Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 6, 2026, 2:06 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 35 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: SIR-Spheres Clear all
Recruiting Phase 2 Interventional

Cemiplimab and Transarterial Radioembolization With Y-90 SIR-S Spheres for the Treatment of Liver Directed Metastatic Breast Cancer

NCT06860815
View directory record Official record
Conditions
Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma, Metastatic Carcinoma in the Liver
Interventions
Biopsy, Biospecimen Collection, Cemiplimab, Computed Tomography, Magnetic Resonance Imaging, Transarterial Radioembolization, Yttrium Y 90 Resin Microspheres
Procedure · Biological · Radiation
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated May 19, 2026 · Synced Sep 6, 2026, 2:06 AM EDT
Not listed Phase 2 Interventional

Internal Radiation Therapy With Y-90 Microspheres, External Radiation Therapy With Tomotherapy, and Fluorouracil in Treating Patients With Newly Diagnosed or Recurrent Pancreatic Cancer and Liver Metastases That Cannot Be Removed By Surgery

NCT00436267
View directory record Official record
Conditions
Metastatic Cancer, Pancreatic Cancer
Interventions
fluorouracil, selective external radiation therapy, tomotherapy, yttrium Y 90 glass microspheres, yttrium Y 90 resin microspheres
Drug · Radiation
Lead sponsor
Goshen Health System
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
1
States / cities
Goshen, Indiana
Source: ClinicalTrials.gov public record
Updated Dec 18, 2013 · Synced Sep 6, 2026, 2:06 AM EDT
Completed Not applicable Interventional Results available

FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer

NCT00724503
View directory record Official record
Conditions
Colorectal Cancer, Colorectal Carcinoma, Liver Metastases
Interventions
SIR-Spheres yttrium-90 microspheres, Systemic chemotherapy (FOLFOX)
Device · Drug
Lead sponsor
Sirtex Medical
Industry
Eligibility
18 Years and older
Enrollment
530 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2015
U.S. locations
21
States / cities
Scottsdale, Arizona • Duarte, California • North Miami Beach, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Mar 25, 2019 · Synced Sep 6, 2026, 2:06 AM EDT
Completed Phase 1 Interventional

CAR-T Hepatic Artery Infusions and Sir-Spheres for Liver Metastases

NCT02416466
View directory record Official record
Conditions
Liver Metastases
Interventions
anti-CEA CAR-T cells, Sir-Spheres
Biological · Device
Lead sponsor
Roger Williams Medical Center
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Mar 25, 2019 · Synced Sep 6, 2026, 2:06 AM EDT
Active, not recruiting Phase 1 Interventional

Yttrium Y-90 Radioembolization in Treating Patients With Metastatic Liver Cancer

NCT03028311
View directory record Official record
Conditions
Metastatic Liver Carcinoma, Stage IV Liver Cancer, Stage IVA Liver Cancer, Stage IVB Liver Cancer
Interventions
Angiography, Computed Tomography, Planar Imaging, Radioembolization, Single Photon Emission Computed Tomography, Technetium Tc-99m Albumin Aggregated, Yttrium Y 90 Resin Microspheres
Procedure · Radiation · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 9, 2026 · Synced Sep 6, 2026, 2:06 AM EDT
Withdrawn Phase 1 Interventional

Capecitabine and Y-90 Radioembolization in Treating Patients With Advanced Bile Duct Cancer in the Liver That Cannot Be Removed by Surgery

NCT03117855
View directory record Official record
Conditions
Bile Duct Adenocarcinoma, Stage III Intrahepatic Cholangiocarcinoma, Stage IVA Intrahepatic Cholangiocarcinoma, Stage IVB Intrahepatic Cholangiocarcinoma
Interventions
Capecitabine, Laboratory Biomarker Analysis, Radioembolization
Drug · Other · Radiation
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2016
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Apr 17, 2017 · Synced Sep 6, 2026, 2:06 AM EDT
Completed Phase 1 Interventional

Pasireotide, Everolimus and Selective Internal Radioembolization Therapy for Unresectable Hepatic Metastases

NCT01469572
View directory record Official record
Conditions
Neuroendocrine Tumors
Interventions
Pasireotide, Sir-sphere Radioembolization, Everolimus
Drug · Procedure
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Oct 17, 2018 · Synced Sep 6, 2026, 2:06 AM EDT
Terminated Phase 2 Interventional

Brachytherapy Radiation Directly to the Liver in Breast Cancer Patients With Metastatic to Liver

NCT00891800
View directory record Official record
Conditions
Breast Cancer Metastatic to the Liver
Interventions
Brachytherapy, SIR-Sphere
Device
Lead sponsor
St. Joseph's Hospital, Florida
Other
Eligibility
18 Years to 85 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Jun 6, 2011 · Synced Sep 6, 2026, 2:06 AM EDT
Not listed Phase 2 Interventional

Definitive Therapy for Oligometastatic Solid Malignancies

NCT01898962
View directory record Official record
Conditions
Stage IV or Recurrent Carcinoma or Sarcoma
Interventions
Complete Surgical Removal, Stereotactic Radiosurgery, Ablative external beam radiation dose, Subtotal surgical removal plus ablative radiation dose, Radioembolization
Procedure · Radiation
Lead sponsor
Rocky Mountain Cancer Centers
Other
Eligibility
18 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2018
U.S. locations
4
States / cities
Aurora, Colorado • Boulder, Colorado • Littleton, Colorado + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2013 · Synced Sep 6, 2026, 2:06 AM EDT
Completed Not applicable Interventional Results available

Low-dose Y90 Treatment Planning for HCC

NCT04172714
View directory record Official record
Conditions
HCC, Cancer of Liver, Cancer
Interventions
SIR-Spheres microspheres
Device
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
3
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Dec 5, 2022 · Synced Sep 6, 2026, 2:06 AM EDT
Withdrawn Phase 1 Interventional

Sorafenib Concurrent With Yttrium-90 Transarterial Radioembolization in Patients With Advanced Hepatocellular Cancer

NCT02288507
View directory record Official record
Conditions
Hepatocellular Cancer
Interventions
Sorafenib, yttrium-90 radioembolization
Drug · Radiation
Lead sponsor
University of Hawaii
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Honolulu, Hawaii
Source: ClinicalTrials.gov public record
Updated Nov 7, 2019 · Synced Sep 6, 2026, 2:06 AM EDT
Completed Phase 2 Interventional Results available

Safety Study of Regorafenib and SIR-Spheres® Microspheres Radioembolization in Patients With Refractory Metastatic Colorectal Cancer With Liver Metastases

NCT02195011
View directory record Official record
Conditions
Colorectal Neoplasms
Interventions
SIR-Spheres, Regorafenib
Device · Drug
Lead sponsor
SCRI Development Innovations, LLC
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
3
States / cities
St. Petersburg, Florida • Kansas City, Missouri • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Dec 4, 2023 · Synced Sep 6, 2026, 2:06 AM EDT
Completed Phase 1 Interventional

Selective Internal Radiation Therapy (SIRT) in Patients With Unresectable Colorectal Cancer Liver Metastases Who Failed Prior Intraarterial Pump Chemotherapy

NCT00972036
View directory record Official record
Conditions
Colon Cancer, Rectal Cancer
Interventions
SIR-spheres® (Selective Internal Radiation Therapy)
Device
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 10, 2014 · Synced Sep 6, 2026, 2:06 AM EDT
Completed Phase 2 Interventional Results available

SIR-Spheres® 90Y Microspheres Treatment of Uveal Melanoma Metastasized to Liver

NCT01473004
View directory record Official record
Conditions
Stage IV Uveal Melanoma
Interventions
Sir-Spheres®
Device
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2024
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 13, 2025 · Synced Sep 6, 2026, 2:06 AM EDT
Completed No phase listed Observational

Yttrium Y 90 Resin Microspheres Data Collection in Unresectable Liver Cancer: the RESIN Study

NCT02685631
View directory record Official record
Conditions
Localized Non-Resectable Adult Liver Carcinoma
Interventions
Yttrium-90 Resin Microspheres
Other
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
18 Years and older
Enrollment
1,653 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
42
States / cities
Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 34 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2021 · Synced Sep 6, 2026, 2:06 AM EDT
Completed Phase 1 Interventional

Study of Capecitabine in Combination With SIR-Spheres in Patients With Advanced Cancer

NCT00604409
View directory record Official record
Conditions
Metastatic Liver Cancer
Interventions
SIRT, capecitabine
Radiation · Drug
Lead sponsor
Fox Chase Cancer Center
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2015
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 6, 2015 · Synced Sep 6, 2026, 2:06 AM EDT
Active, not recruiting No phase listed Observational

Pilot Study to Assess Lung Shunting of Yttrium-90 Microspheres Using PET/CT

NCT02119065
View directory record Official record
Conditions
Advanced Adult Primary Liver Cancer, Liver Metastases, Localized Unresectable Adult Primary Liver Cancer, Recurrent Adult Primary Liver Cancer
Interventions
positron emission tomography, computed tomography
Procedure
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2026
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 10, 2025 · Synced Sep 6, 2026, 2:06 AM EDT
Completed Phase 3 Interventional Results available

FOLFOX6m Plus SIR-Spheres Microspheres vs FOLFOX6m Alone in Patients With Liver Mets From Primary Colorectal Cancer

NCT01721954
View directory record Official record
Conditions
Colorectal Cancer Metastatic
Interventions
FOLFOX6m, SIR-Spheres microspheres
Drug · Device
Lead sponsor
Sirtex Medical
Industry
Eligibility
18 Years and older
Enrollment
209 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
18
States / cities
Duarte, California • Orlando, Florida • Pembroke Pines, Florida + 15 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2019 · Synced Sep 6, 2026, 2:06 AM EDT
Not yet recruiting Not applicable Interventional

End Hole vs. Pressure-Modulated Delivery of Y-90 Resin Microspheres to Liver Metastases.

NCT07791446
View directory record Official record
Conditions
Liver Metastases, Tumor
Interventions
The TriNav Infusion Systems, Standard End Hole Microcatheter
Device
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Sep 6, 2026, 2:06 AM EDT
Recruiting Not applicable Interventional

Y90 Radioembolization Dose Delivery and Radiation Exposure Assessment

NCT03686709
View directory record Official record
Conditions
Hepatocellular Carcinoma, Radiation Exposure
Interventions
Post therapy PET/CT Imaging
Diagnostic Test
Lead sponsor
University of Tennessee
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 26, 2018 · Synced Sep 6, 2026, 2:06 AM EDT
Not listed Phase 1Phase 2 Interventional

Yttrium90, Ipilimumab, & Nivolumab for Uveal Melanoma With Liver Metastases

NCT02913417
View directory record Official record
Conditions
Uveal Melanoma, Hepatic Metastases
Interventions
SIR-Spheres® Yttrium 90, ipilimumab, nivolumab
Device · Drug
Lead sponsor
David Minor, MD
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
3
States / cities
San Francisco, California • Chicago, Illinois • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 18, 2021 · Synced Sep 6, 2026, 2:06 AM EDT
Active, not recruiting Phase 1 Interventional

Durvalumab and Tremelimumab After Radioembolization for the Treatment of Unresectable, Locally Advanced Liver Cancer

NCT04605731
View directory record Official record
Conditions
BCLC Stage B Hepatocellular Carcinoma, BCLC Stage C Hepatocellular Carcinoma, Locally Advanced Hepatocellular Carcinoma, Stage III Hepatocellular Carcinoma AJCC v8, Stage IIIA Hepatocellular Carcinoma AJCC v8, Stage IIIB Hepatocellular Carcinoma AJCC v8, Stage IV Hepatocellular Carcinoma AJCC v8, Stage IVA Hepatocellular Carcinoma AJCC v8, Stage IVB Hepatocellular Carcinoma AJCC v8, Unresectable Hepatocellular Carcinoma
Interventions
Durvalumab, Tremelimumab
Biological
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Apr 19, 2026 · Synced Sep 6, 2026, 2:06 AM EDT
Terminated Phase 2 Interventional Results available

Study of Lanreotide in Patients With Metastatic Gastrointestinal Neuroendocrine Tumors Who Are Undergoing Liver-directed Radioembolization With Yttrium-90 Microspheres

NCT02859064
View directory record Official record
Conditions
Neuroendocrine Tumors, Gastrointestinal Neoplasms, Carcinoid Tumors
Interventions
Lanreotide, Y-90 microspheres
Drug · Device
Lead sponsor
SCRI Development Innovations, LLC
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
3
States / cities
Denver, Colorado • Kansas City, Missouri • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Dec 4, 2023 · Synced Sep 6, 2026, 2:06 AM EDT
Terminated Not applicable Interventional

Gemcitabine-Cisplatin-90Y TARE for Unresectable Intrahepatic Cholangiocarcinoma

NCT02512692
View directory record Official record
Conditions
Intrahepatic Cholangiocarcinoma
Interventions
SIR-Spheres microspheres (Yttrium-90 Microspheres), Gemcitabine, Cisplatin
Device · Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Nov 17, 2024 · Synced Sep 6, 2026, 2:06 AM EDT